Basic Materials [ 12/13 ] | Specialty Chemicals [ 101/163 ]
NYSE | Common Stock
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa.
The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.
It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies.
In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services.
Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, and compound management services.
The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 26, 24 | 0.22 Decreased by -24.14% | 0.20 Increased by +10.00% |
| Feb 14, 24 | 0.25 Decreased by -21.88% | 0.22 Increased by +13.64% |
| Oct 27, 23 | 0.25 Decreased by -26.47% | 0.26 Decreased by -3.85% |
| Jul 28, 23 | 0.28 Decreased by -24.32% | 0.29 Decreased by -3.45% |
| Apr 28, 23 | 0.29 Decreased by -23.68% | 0.28 Increased by +3.57% |
| Feb 3, 23 | 0.32 Decreased by -11.11% | 0.30 Increased by +6.67% |
| Oct 28, 22 | 0.34 Decreased by -2.86% | 0.33 Increased by +3.03% |
| Jul 28, 22 | 0.37 Increased by +5.71% | 0.38 Decreased by -2.63% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 1.68 B Decreased by -5.65% | 60.40 M Decreased by -50.29% | Increased by +3.60% Decreased by -47.31% |
| Dec 31, 23 | 1.72 B Decreased by -77.07% | 98.50 M Increased by +4.79% | Increased by +5.72% Increased by +356.93% |
| Sep 30, 23 | 1.72 B Decreased by -7.34% | 108.40 M Decreased by -35.09% | Increased by +6.30% Decreased by -29.95% |
| Jun 30, 23 | 1.74 B Decreased by -8.72% | -7.30 M Decreased by -103.90% | Decreased by -0.42% Decreased by -104.27% |
| Mar 31, 23 | 1.78 B Decreased by -8.72% | 121.50 M Decreased by -36.19% | Increased by +6.82% Decreased by -30.09% |
| Dec 31, 22 | 7.51 B Increased by +293.81% | 94.00 M Increased by 0.00% | Increased by +1.25% Decreased by -74.61% |
| Sep 30, 22 | 1.86 B Increased by +1.21% | 167.00 M Increased by +6.51% | Increased by +9.00% Increased by +5.23% |
| Jun 30, 22 | 1.91 B Increased by +2.79% | 187.40 M Increased by +18.76% | Increased by +9.81% Increased by +15.53% |